Citations (49)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Sarah-Jane F. Stewart, Zoe Moon & Rob Horne. (2023) Medication nonadherence: health impact, prevalence, correlates and interventions. Psychology & Health 38:6, pages 726-765.
Read now
Read now
Charlotte Druart, Souraya El Sankari & Vincent van Pesch. (2018) Long-term safety and real-world effectiveness of fingolimod in relapsing multiple sclerosis. Patient Related Outcome Measures 9, pages 1-10.
Read now
Read now
Michael Munsell, Molly Frean, Joseph Menzin & Amy L Phillips. (2017) An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug. Patient Preference and Adherence 11, pages 55-62.
Read now
Read now
Antonios Bayas & Mathias Mäurer. (2015) Teriflunomide for the treatment of relapsing–remitting multiple sclerosis: patient preference and adherence. Patient Preference and Adherence 9, pages 265-274.
Read now
Read now
Antonios Bayas, Jean Christophe Ouallet, Boris Kallmann, Raymond Hupperts, Ulrich Fulda & Kurt Marhardt. (2015) Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study. Expert Opinion on Drug Delivery 12:8, pages 1239-1250.
Read now
Read now
Raymond Hupperts, Veit Becker, Janne Friedrich, Claudio Gobbi, Antonio Vasco Salgado, Bjørn Sperling & Xiaojun You. (2015) Multiple sclerosis patients treated with intramuscular IFN-β-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfaction. Expert Opinion on Drug Delivery 12:1, pages 15-25.
Read now
Read now
Ann Crawford, Holly Mara, Laura McCatty & Regina Pelfrey. (2014) Managing treatment fatigue in patients with multiple sclerosis on long-term therapy: the role of multiple sclerosis nurses. Patient Preference and Adherence 8, pages 1093-1099.
Read now
Read now
Janice L. Jones, Donna J. Scheidt, Ranbir S. Kaushal & Cathryn A. Carroll. (2013) Assessing the role of patient support services on adherence rates in patients using glatiramer acetate for relapsing-remitting multiple sclerosis. Journal of Medical Economics 16:2, pages 213-220.
Read now
Read now
J. I. Ivanova, R. E. Bergman, H. G. Birnbaum, A. L. Phillips, M. Stewart & D. M. Meletiche. (2012) Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US. Journal of Medical Economics 15:3, pages 601-609.
Read now
Read now
Krithika Rajagopalan, Richard A. Brook, Ian A. Beren & Nathan L. Kleinman. (2011) Comparing costs and absences for multiple sclerosis among US employees: pre- and post-treatment initiation. Current Medical Research and Opinion 27:1, pages 179-188.
Read now
Read now
David W Brandes. (2010) The role of glatiramer acetate in the early treatment of multiple sclerosis. Neuropsychiatric Disease and Treatment 6, pages 329-336.
Read now
Read now
J. de Sá, G. Urbano & L. Reis. (2010) Assessment of new application system in Portuguese patients with relapsing-remitting multiple sclerosis. Current Medical Research and Opinion 26:9, pages 2237-2242.
Read now
Read now
Srikant Rangaraju, Victor Chi, Michael W Pennington & K George Chandy. (2009) Kv1.3 potassium channels as a therapeutic target in multiple sclerosis. Expert Opinion on Therapeutic Targets 13:8, pages 909-924.
Read now
Read now
Articles from other publishers (36)
Raed Al-Roughani, Magd Zakaria, Edward J. Cupler & Karim Taha. (2023) Adherence to subcutaneous interferon beta-1a treatment among patients with relapsing multiple sclerosis: the MAIN-MS study. Frontiers in Neurology 14.
Crossref
Crossref
Aliza Bitton Ben-Zacharia, Bryan Walker, Amy Perrin Ross, Carlo Tornatore, Natalie C. Edwards, Yvette Lipman & Amy L. Phillips. (2023) Factors Associated With Disease-Modifying Therapy Adherence and Persistence in Multiple Sclerosis: A Scoping Literature Review. International Journal of MS Care 25:5, pages 188-195.
Crossref
Crossref
Serkan Demir, Melih Tutuncu, Cihat Uzunkopru, Haluk Gumus, Sedat Sen, Tuncay Gunduz, Ipek Gungor Dogan, Bilge Piri Cinar, Sila Usar Incirli, Mesude Tutuncu, Kamil Mavi, Suha Yuksel, Rifat Erdem Togrol, Ayse Sagduyu Kocaman & Aksel Siva. (2021) A comprehensive assessment of patient experience and disease-related awareness in multiple sclerosis: A questionnaire-based nation-wide survey in Turkey. Multiple Sclerosis and Related Disorders 52, pages 103005.
Crossref
Crossref
Andréa D. Fuzimoto & Francesco Brigo. (2020) The “Treatise on the spleen and stomach” (Pí Wèi Lùn) as the first record of multiple sclerosis in the medical literature – A hypothesis based on the analysis of clinical presentation and herbal medicine. Journal of Traditional and Complementary Medicine 10:3, pages 288-300.
Crossref
Crossref
Kyle Smoot, Kateri J Spinelli, Tamela Stuchiner, Lindsay Lucas, Chiayi Chen, Lois Grote, Elizabeth Baraban, Kiren Kresa-Reahl & Stanley Cohan. (2017) Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center. Multiple Sclerosis Journal 24:7, pages 942-950.
Crossref
Crossref
Manuela Glattacker, Jürgen M. Giesler, Katharina Klindtworth & Angelika Nebe. (2018) Rehabilitation use in multiple sclerosis: Do illness representations matter?. Brain and Behavior 8:6.
Crossref
Crossref
Archibald de Ceuninck van Capelle, Hanneke van der Meide, Frans J. H. Vosman & Leo. H. Visser. (2017) A qualitative study assessing patient perspectives in the process of decision-making on disease modifying therapies (DMT’s) in multiple sclerosis (MS). PLOS ONE 12:8, pages e0182806.
Crossref
Crossref
J. Theodore Phillips, Stephanie Agrella & Robert J. Fox. (2017) Dimethyl Fumarate. International Journal of MS Care 19:2, pages 74-83.
Crossref
Crossref
Barry Hendin, DeRen Huang, Sibyl Wray, Robert T Naismith, Sheri Rosenblatt, Javier Zambrano & Brian Werneburg. (2017) Subcutaneous peginterferon β-1a injection-site reaction experience and mitigation: Delphi analysis of the ALLOW study. Neurodegenerative Disease Management 7:1, pages 39-47.
Crossref
Crossref
Irene Cortese & Avindra Nath. 2017. Neuroimmune Pharmacology. Neuroimmune Pharmacology
713
736
.
June Halper, Diego Centonze, Scott D. Newsome, DeRen Huang, Christopher Robertson, Xiaojun You, Guido Sabatella, Vladimir Evilevitch & Leslie Leahy. (2016) Management Strategies for Flu-Like Symptoms and Injection-Site Reactions Associated with Peginterferon Beta-1a. International Journal of MS Care 18:4, pages 211-218.
Crossref
Crossref
Rocco Haase, Jennifer S. Kullmann & Tjalf Ziemssen. (2016) Therapy satisfaction and adherence in patients with relapsing–remitting multiple sclerosis: the THEPA-MS survey. Therapeutic Advances in Neurological Disorders 9:4, pages 250-263.
Crossref
Crossref
Jill R Settle, Heidi W Maloni, McKenzie Bedra, Joseph Finkelstein, Min Zhan & Mitchell T Wallin. (2015) Monitoring medication adherence in multiple sclerosis using a novel web-based tool: A pilot study. Journal of Telemedicine and Telecare 22:4, pages 225-233.
Crossref
Crossref
T. Spelman, L. Mekhael, T. Burke, H. Butzkueven, S. Hodgkinson, E. Havrdova, D. Horakova, P. Duquette, G. Izquierdo, F. Grand'Maison, P. Grammond, M. Barnett, J. Lechner‐Scott, R. Alroughani, M. Trojano, A. Lugaresi, F. Granella, E. Pucci & S. Vucic. (2016) Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis. European Journal of Neurology 23:4, pages 729-736.
Crossref
Crossref
Zaza Katsarava, Birgit Ehlken, Volker Limmroth, Kirsi Taipale, Sarita Noemi Patel, Gabriele Niemczyk, Karin Rehberg-Weber & Colin Wernsdörfer. (2015) Adherence and cost in multiple sclerosis patients treated with IM IFN beta-1a: impact of the CARE patient management program. BMC Neurology 15:1.
Crossref
Crossref
J. Theodore Phillips, April A. Erwin, Stephanie Agrella, Marcelo Kremenchutzky, John F. Kramer, Malcolm J. M. Darkes, Jonathan Kendter, Heather Abourjaily, Jitesh Rana & Robert J. Fox. (2015) Consensus Management of Gastrointestinal Events Associated with Delayed-Release Dimethyl Fumarate: A Delphi Study. Neurology and Therapy 4:2, pages 137-146.
Crossref
Crossref
Cécile Donzé, Lucie Malapel, Arnaud Kwiatkowski, Bruno Lenne, Pierre Louchard, Véronique Neuville & Patrick Hautecoeur. (2015) Treatment discontinuation in multiple sclerosis: The French Web-based survey ALLIANCE. Multiple Sclerosis Journal - Experimental, Translational and Clinical 1, pages 205521731560072.
Crossref
Crossref
Jonathan Calkwood, Bruce Cree, Heidi Crayton, Daniel Kantor, Brian Steingo, Luigi Barbato, Ron Hashmonay, Neetu Agashivala, Kevin McCague, Nadia Tenenbaum & Keith Edwards. (2014) Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hocanalyses of the EPOC trial. BMC Neurology 14:1.
Crossref
Crossref
Raymond Hupperts, Lizette Ghazi-Visser, Ana Martins Silva, Michalis Arvanitis, Hanna Kuusisto, Kurt Marhardt & Nikolaos Vlaikidis. (2014) The STAR Study: A Real-World, International, Observational Study of the Safety and Tolerability of, and Adherence to, Serum-Free Subcutaneous Interferon β-1a in Patients With Relapsing Multiple Sclerosis. Clinical Therapeutics 36:12, pages 1946-1957.
Crossref
Crossref
Simon A. Broadley, Michael H. Barnett, Mike Boggild, Bruce J. Brew, Helmut Butzkueven, Robert Heard, Suzanne Hodgkinson, Allan G. Kermode, Jeannette Lechner-Scott, Richard A.L. Macdonell, Mark Marriott, Deborah F. Mason, John Parratt, Stephen W. Reddel, Cameron P. Shaw, Mark Slee, Judith Spies, Bruce V. Taylor, William M. Carroll, Trevor J. Kilpatrick, John King, Pamela A. McCombe, John D. Pollard & Ernest Willoughby. (2014) Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 3 Treatment practicalities and recommendations. Journal of Clinical Neuroscience 21:11, pages 1857-1865.
Crossref
Crossref
Edward Fox, Keith Edwards, Gordon Burch, Daniel R. Wynn, Chris LaGanke, Heidi Crayton, Samuel F. Hunter, Cynthia Huffman, Edward Kim, Linda Pestreich, Kevin McCague & Luigi Barbato. (2014) Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders 3:5, pages 607-619.
Crossref
Crossref
Rebekah L. Hanson, Mitra Habibi, Nehrin Khamo, Sherif Abdou & JoAnn Stubbings. (2014) Integrated clinical and specialty pharmacy practice model for management of patients with multiple sclerosis. American Journal of Health-System Pharmacy 71:6, pages 463-469.
Crossref
Crossref
Ronald A. CohenRonald A. Cohen. 2014. The Neuropsychology of Attention. The Neuropsychology of Attention
429
489
.
Sanober Nusrat, David Levinthal & Klaus Bielefeldt. (2013) Hospitalization Rates and Discharge Status in Multiple Sclerosis. Multiple Sclerosis International 2013, pages 1-7.
Crossref
Crossref
Raed Alroughani & Anil Thussu. (2012) Adherence to First-Line Disease-Modifying Therapy for Multiple Sclerosis in Kuwait. International Journal of MS Care 14:1, pages 17-24.
Crossref
Crossref
Virginia A DevonshireElisabetta Verdun di Cantogno. (2011) Review of subcutaneous interferon β-1a, delivered via the electronic self-injection device RebiSmart™, for the treatment of multiple sclerosis. Therapeutic Delivery 2:11, pages 1455-1465.
Crossref
Crossref
Therese Burke, Sara Dishon, Lynn McEwan & Jennifer Smrtka. (2011) The Evolving Role of the Multiple Sclerosis Nurse. International Journal of MS Care 13:3, pages 105-112.
Crossref
Crossref
Colleen E. Miller & Margaret A. Umhauer. (2011) Emerging Oral Therapies for Multiple Sclerosis. Journal of Neuroscience Nursing 43:1, pages 3-14.
Crossref
Crossref
Ralf Gold. (2011) Oral Therapies for Multiple Sclerosis. CNS Drugs 25:1, pages 37-52.
Crossref
Crossref
Hiangkiat Tan, Qian Cai, Sonalee Agarwal, Judith J. Stephenson & Siddhesh Kamat. (2010) Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Advances in Therapy 28:1, pages 51-61.
Crossref
Crossref
Amy Perrin Ross & Ben W. Thrower. (2010) Recent Developments in the Early Diagnosis and Management of Multiple Sclerosis. Journal of Neuroscience Nursing 42:6, pages 342-353.
Crossref
Crossref
E. Arroyo, M. González, C. Grau, C. Arnal, M. Bujanda, P. de Castro, L. Grau, M. Martínez, C. Ramo, V. Sánchez & O. Sánchez-Soliño. (2010) Herramientas para mejorar la adherencia al tratamiento con inmunomoduladores en pacientes con esclerosis múltiple. Neurología 25:9, pages 544-551.
Crossref
Crossref
Jennifer Smrtka, Christina Caon, Carol Saunders, Brenda L. Becker & Nancy Baxter. (2010) Enhancing Adherence Through Education. Journal of Neuroscience Nursing 42:5, pages S19-S29.
Crossref
Crossref
Cristina Negrini, G. Belletti, M. I. Famà & C. Pozzilli. (2013) La gestione dei pazienti affetti da sclerosi multiplaManagement of multiple sclerosis patients: value analysis of a specialist nursing home care program. Giornale Italiano di Health Technology Assessment 3:1, pages 31-40.
Crossref
Crossref
E. Arroyo, M. González, C. Grau, C. Arnal, M. Bujanda, P. de Castro, L. Grau, M. Martínez, C. Ramo, V. Sánchez & O. Sánchez-Soliño. (2010) Proposals to improve adherence to immunomodulatory therapies in patients with multiple sclerosis. Neurología (English Edition) 25:9, pages 544-551.
Crossref
Crossref
. (2009) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 18:9.
Crossref
Crossref